Infuseon, OncoSynergy Partner on Direct Delivery of mAb Therapy for Glioblastoma

Infuseon, OncoSynergy Partner on Direct Delivery of mAb Therapy for Glioblastoma

The firms’ strategic alliance aims to establish proof of concept that OS2966 can be delivered directly to the brain

Caribou's Vonnie Estes to Receive 2017 Rosalind Franklin Award

Caribou's Vonnie Estes to Receive 2017 Rosalind Franklin Award

The Award is sponsored by the Rosalind Franklin Society, whose goal is to support and showcase the careers of eminent women in science.

eFFECTOR Collaborates with Pfizer and Merck on Immuno-Oncology

eFFECTOR Collaborates with Pfizer and Merck on Immuno-Oncology

eFT508 and avelumab are immunotherapies, designed to harness the body's own immune system in fighting cancer.

AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors

AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors

The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology. 

Atreca and Dana-Farber to partner on cancer immunotherapy

Atreca and Dana-Farber to partner on cancer immunotherapy

Atreca will apply its Immune Repertoire Capture® technology to generate sequences of native antibodies and TCRs from patients.

Caribou's Rachel Haurwitz speaks at TechCrunch NYC

Caribou's Rachel Haurwitz speaks at TechCrunch NYC

The Caribou CEO and co-founder spoke at TechCrunch Disrupt about the ethical and legal challenges of CRISPR technology.

Bioverativ to buy True North Therapeutics for $400M

Bioverativ to buy True North Therapeutics for $400M

True North is a Mission Bay Capital portfolio company pursuing therapies that target the complement system to treat rare diseases.

Symic Bio Secures $30 Million Series B Financing

Symic Bio Secures $30 Million Series B Financing

Symic recently graduated from the QB3@953 incubator after several years' residence.

Vinod Khosla leads $24.5M Series A for Two Pore Guys

Vinod Khosla leads $24.5M Series A for Two Pore Guys

Two Pore Guys was spun out of research at UC Santa Cruz by William Dunbar and Trevor Morin. Their core technology is a handheld molecular sensor based on solid-state nanopores.

Circle Pharma expands its Series A funding

Circle Pharma expands its Series A funding

Circle was founded as a collaboration between Matt Jacobson at UCSF and Scott Lokey at UC Santa Cruz. The company is designing macrocyclic peptide therapeutics.